Types of Enzyme Inhibition

Why This Matters

Enzyme inhibition is the foundation for understanding how drugs work, how metabolic pathways are regulated, and how cells fine-tune their chemistry in real time. Each inhibition type tells a story about where the inhibitor binds, when it binds (to free enzyme, ES complex, or both), and what happens to $V_{max}$ and $K_m$ as a result.

Don't just memorize that competitive inhibition increases K_m}. Understand why it does: the inhibitor blocks the active site, so you need more substrate to outcompete it. Master the mechanism, and the kinetic changes follow logically. That reasoning is exactly what exam questions test, especially when you're handed a Lineweaver-Burk plot or kinetic data and need to identify the inhibition type.

---

Reversible Inhibition at the Active Site

These inhibitors compete directly with substrate for access to the enzyme's active site. Because binding is reversible and mutually exclusive with substrate, increasing substrate concentration can overcome the inhibition.

Competitive Inhibition

• Inhibitor binds the active site. It structurally resembles the substrate and directly blocks substrate access. Think of methotrexate, which mimics dihydrofolate and competes for dihydrofolate reductase.
• $V_{max}$ unchanged, $K_m$ increases. You can still reach maximum velocity, but you need more substrate to get there. In other words, the apparent affinity for substrate decreases.
• Overcome by excess substrate. This is the hallmark feature. Flood the system with substrate and you outcompete the inhibitor. On a Lineweaver-Burk plot, the lines converge at the same y-intercept (same $V_{max}$) but the x-intercept shifts (higher apparent $K_m$).

---

Reversible Inhibition Away from the Active Site

These inhibitors bind to sites other than the active site, causing conformational changes or blocking catalysis without directly competing for substrate binding. The key distinction is whether the inhibitor prefers free enzyme (E), the ES complex, or both equally.

Non-Competitive Inhibition

• Binds an allosteric site with equal affinity for E and ES. Substrate can still bind, but the enzyme-inhibitor complex is catalytically inactive or impaired.
• $V_{max}$ decreases, $K_m$ unchanged. Fewer functional enzyme molecules means lower maximum velocity, but substrate binding affinity isn't affected.
• Cannot be overcome by adding substrate. Since the inhibitor doesn't compete for the active site, more substrate won't help. On a Lineweaver-Burk plot, the y-intercept increases (lower $V_{max}$) while the x-intercept stays the same.

Uncompetitive Inhibition

• Binds only to the ES complex. The inhibitor has no affinity for free enzyme. It waits for substrate to bind first, then locks onto the ES complex.
• Both $V_{max}$ and $K_m$ decrease. The inhibitor traps ES complexes, removing them from the reaction. The apparent $K_m$ drops because substrate binding appears enhanced, but the bound substrate can't be converted to product. On a Lineweaver-Burk plot, this produces parallel lines (both slope and intercepts change, but the slope itself stays constant).
• Common in multi-substrate reactions. Look for this pattern when enzymes have ordered binding mechanisms.

Mixed Inhibition

• Binds both E and ES, but with different affinities. This creates a spectrum between competitive-like and uncompetitive-like behavior, depending on which form the inhibitor prefers.
• $V_{max}$ decreases; $K_m$ can increase or decrease. If the inhibitor prefers free enzyme ($\alpha > \alpha'$), $K_m$ increases. If it prefers the ES complex ($\alpha' > \alpha$), $K_m$ decreases. On a Lineweaver-Burk plot, the lines intersect to the left of the y-axis but not on the x-axis.
• Most "non-competitive" inhibitors are actually mixed. True non-competitive inhibition (perfectly equal affinity for E and ES) is relatively rare in nature. Mixed inhibition is the more general case.

---

Irreversible Inhibition

Unlike reversible inhibitors that establish equilibrium, irreversible inhibitors permanently disable enzymes. Covalent bond formation means the enzyme molecule is lost from the active pool entirely.

Irreversible Inhibition

• Forms covalent bonds with the enzyme. These inhibitors typically modify active site residues essential for catalysis, often targeting nucleophilic amino acids like serine, cysteine, or histidine. A classic example: aspirin irreversibly acetylates a serine residue in cyclooxygenase (COX).
• $V_{max}$ decreases progressively. Active enzyme concentration drops over time. The effect is time-dependent and cumulative, which distinguishes it from reversible inhibition on kinetic assays.
• Cannot be reversed by dilution or substrate. The enzyme is permanently inactivated. The cell must synthesize new enzyme to recover activity. This is why a single dose of aspirin affects platelets for their entire 7–10 day lifespan: platelets lack a nucleus and can't make new COX.

---

Regulatory Inhibition Mechanisms

These inhibition patterns serve important physiological roles in controlling metabolic flux. Cells use these mechanisms to respond to changing conditions and maintain homeostasis.

Allosteric Inhibition

• Binding at regulatory sites causes conformational change. The enzyme shifts to a lower-activity state (the T-state in the concerted/MWC model). Allosteric enzymes typically have multiple subunits, and inhibitor binding to one subunit affects the others.
• Often produces sigmoidal kinetics. Cooperative binding means the enzyme doesn't follow simple Michaelis-Menten behavior. Look for S-shaped $v$ vs. $[S]$ curves instead of the usual hyperbolic shape.
• Critical for feedback regulation. End products of metabolic pathways often inhibit early enzymes allosterically, preventing overproduction. For example, ATP inhibits phosphofructokinase-1 (PFK-1) in glycolysis when the cell's energy charge is high.

Substrate Inhibition

• Excess substrate decreases reaction rate. At high concentrations, a second substrate molecule can bind nonproductively to the ES complex, forming a dead-end $SES$ complex that can't proceed to product.
• Creates a bell-shaped velocity curve. Rate increases with substrate initially (normal Michaelis-Menten behavior), then decreases at very high concentrations.
• Physiologically important safety mechanism. This prevents runaway reactions and helps maintain steady-state metabolite levels. Many enzymes that handle potentially toxic substrates display this property.

---

Quick Reference Table

---

Self-Check Questions

1. You're analyzing a Lineweaver-Burk plot and notice that adding an inhibitor increases the slope but doesn't change the y-intercept. What type of inhibition is this, and what happened to $K_m$ and $V_{max}$?

2. Which two inhibition types both decrease $V_{max}$ while leaving $K_m$ unchanged? What distinguishes them mechanistically?

3. A pharmaceutical company wants to design a drug that can be overcome by the body's natural substrate if concentrations rise. Which inhibition type should they target, and why?

4. Compare uncompetitive and mixed inhibition: both affect $K_m$, but in what direction does $K_m$ change for each, and what does this tell you about where the inhibitor binds?

5. An enzyme shows normal Michaelis-Menten kinetics at low substrate concentrations but decreased velocity at very high substrate concentrations. What type of inhibition is occurring, and how would you distinguish this from allosteric inhibition on a kinetic plot?